Grochow LB - Search Results

1

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. Gore SD, et al. Among authors: grochow lb. Clin Cancer Res. 2002 Apr;8(4):963-70. Clin Cancer Res. 2002. PMID: 11948101 Clinical Trial.

2

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA. Gilbert J, et al. Clin Cancer Res. 2001 Aug;7(8):2292-300. Clin Cancer Res. 2001. PMID: 11489804 Clinical Trial.

3

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH. Rowinsky EK, et al. Among authors: grochow lb. J Clin Oncol. 1994 Oct;12(10):2193-203. doi: 10.1200/JCO.1994.12.10.2193. J Clin Oncol. 1994. PMID: 7931489 Clinical Trial.

4

Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.

Kennedy MJ, Zahurak ML, Donehower RC, Noe D, Grochow LB, Sartorius S, Chen TL, Bowling K, Duerr M, Rowinsky EK. Kennedy MJ, et al. Among authors: grochow lb. Clin Cancer Res. 1998 Feb;4(2):349-56. Clin Cancer Res. 1998. PMID: 9516922 Clinical Trial.

5

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.

Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC. Rowinsky EK, et al. Among authors: grochow lb. Clin Cancer Res. 1997 Mar;3(3):401-7. Clin Cancer Res. 1997. PMID: 9815698 Clinical Trial.

6

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB. Gore SD, et al. Among authors: grochow lb. Clin Cancer Res. 2001 Aug;7(8):2330-9. Clin Cancer Res. 2001. PMID: 11489809 Clinical Trial.

7

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC. Carducci MA, et al. Among authors: grochow lb. Clin Cancer Res. 2001 Oct;7(10):3047-55. Clin Cancer Res. 2001. PMID: 11595694 Clinical Trial.

8

Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.

Rowinsky EK, Noe DA, Orr DW, Grochow LB, Ettinger DS, Donehower RC. Rowinsky EK, et al. Among authors: grochow lb. J Natl Cancer Inst. 1988 Jul 6;80(9):671-8. doi: 10.1093/jnci/80.9.671. J Natl Cancer Inst. 1988. PMID: 3373556

9

Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.

Rowinsky EK, Ettinger DS, McGuire WP, Noe DA, Grochow LB, Donehower RC. Rowinsky EK, et al. Among authors: grochow lb. Cancer Res. 1987 Nov 1;47(21):5788-95. Cancer Res. 1987. PMID: 3664482

10

Camptothecin analogues: studies from the Johns Hopkins Oncology Center.

Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC. Slichenmyer WJ, et al. Among authors: grochow lb. Cancer Chemother Pharmacol. 1994;34 Suppl:S53-7. doi: 10.1007/BF00684864. Cancer Chemother Pharmacol. 1994. PMID: 7520844 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters